Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;38(2):185-195.
doi: 10.1002/da.23114. Epub 2020 Nov 22.

Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report

Sidney Zisook  1   2 , Gary R Johnson  3 , Paul Hicks  4 , Peijun Chen  5 , Thomas Beresford  6 , James P Michalets  7 , Sanjai Rao  1 , Michael E Thase  8 , James Wilcox  9 , Varadan Sevilimedu  3 , Somaia Mohamed  10
Affiliations

Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report

Sidney Zisook et al. Depress Anxiety. 2021 Feb.

Abstract

Background: This secondary analysis of the VA Augmentation and Switching Treatments for Depression study compared the continuation phase treatment outcomes of three commonly used second-step treatment strategies following at least one prior failed medication treatment attempt.

Methods: In total, 1522 outpatients with MDD were randomized to switching to bupropion-SR (S-BUP), combining with bupropion-SR (C-BUP), or augmenting with aripiprazole (A-ARI). Following 12 weeks of acute phase treatment, 725 entered the 24-week continuation treatment phase. Depressive symptom severity, relapse, "emergent" remission, anxiety, suicidal ideation, quality of life, health status, and side effects were compared.

Results: We did not find clinically significant differential treatment effects with the exception that A-ARI was associated with less anxiety than S-BUP or C-BUP. Participants who entered continuation treatment as remitters had milder depressive symptom severity and lower relapse rates than those not in remission; they also experienced more improvement on most other outcomes. A-ARI was associated with less anxiety, insomnia, and dry mouth but more somnolence, extrapyramidal effects, akathisia, abnormal laboratory values, and appetite and weight gain.

Conclusions: Continuation treatment is a dynamic period. Regardless of the treatment, participants who entered continuation treatment at Week 12 in full remission continued to have better outcomes over the subsequent 24 weeks than those who were not in remission at the start of the continuation phase.

Trial registration: ClinicalTrials.gov NCT01421342.

Keywords: antidepressants; continuation phase treatment; major depressive disorder; mood disorders-unipolar; relapse; remission.

PubMed Disclaimer

References

REFERENCES

    1. American Psychiatric Association (APA). (2010). APA practice guideline for the treatment of patients with major depressive disorder (3rd ed.). Author.
    1. Barnes, T. R. (1989). A rating scale for drug-induced akathisia. The British Journal of Psychiatry, 154(5), 672-676.
    1. Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology, 56(6), 893-897.
    1. Borges, S., Chen, Y. F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A. (2014). Review of maintenance trials for major depressive disorder: A 25-year perspective from the US Food and Drug Administration. The Journal of Clinical Psychiatry, 75(3), 205-214. https://doi.org/10.4088/JCP.13r08722
    1. Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin, 29, 321-326.

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources